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ABSTRACT 
Background: In Wilson’s disease, ATP7B mutations impair copper excretion with 
liver or brain damage. Healthy transplanted hepatocytes repopulate liver, excrete copper 
and reverse hepatic damage in animal models of Wilson’s disease. In Fah-/- mice with 
tyrosinemia and alpha-1 antitrypsin mutant mice, liver disease is resolved by expansions of 
healthy hepatocytes derived from transplanted healthy bone marrow stem cells. This 
potential of stem cells has not been defined for Wilson’s disease. Methods: In diseased 
Atp7b-/- mice we reconstituted bone marrow with donor cells expressing green fluorescent 
protein reporter from healthy transgenic mice. Mature hepatocytes originating from donor 
bone marrow were identified by immunostaining for green fluorescence protein and bile 
canalicular marker, dipeptidylpeptidase-4. Mesenchymal and inflammatory cell markers 
were used for other cells from donor bone marrow cells. Gene expression, liver tests and 
tissues were analyzed for outcomes in Atp7b-/- mice. Results: After bone marrow 
transplantation in Atp7b-/- mice, donor-derived hepatocytes containing bile canaliculi 
appeared within weeks. Despite this maturity, donor-derived hepatocytes neither divided 
nor expanded. Liver of Atp7b-/- mice was not repopulated by donor-derived hepatocytes: 
Atp7b mRNA remained undetectable; liver tests, copper content and fibrosis actually 
worsened. Restriction of proliferation in hepatocytes accompanied oxidative DNA damage. 
By contrast, donor-derived mesenchymal and inflammatory cells extensively proliferated. 
These contributed to fibrogenesis through greater expression of inflammatory cytokines. 
Conclusion: In Wilson’s disease, donor bone marrow-derived cells underwent different 
fates: hepatocytes failed to proliferate; inflammatory cells proliferated to worsen disease 
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outcomes. This knowledge will help guide stem cell therapies for conditions with pro-
inflammatory or pro-fibrogenic microenvironments.  
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INTRODUCTION 
Physiologically-regulated gene expression could be restored by repopulating liver 
with healthy cells. This offers opportunities for therapeutics and translational models 1-6. 
Liver conditions constitute multiple targets for cell therapy 7. The potential of stem cell-
derived lineages has been largely understood at gene expression levels 8; 9. This may not 
accurately predict whether after transplantation cells will engraft and proliferate. As mature 
hepatocytes possess unique structures (gap junctions, bile canaliculi) 10; 11, this should allow 
alternative ways to determine fates of stem cells.  
In Fah-/- mouse model of hereditary tyrosinemia, transplanted adult hepatocytes 
repopulate liver and correct disease 3; 4. Hepatocytes originating from donor cells after bone 
marrow transplantation (BMT) exerted similar outcomes 3. Also, in mice with mutant 
human alpha-1 antitrypsin, liver injury improved after intraportal transplantation of healthy 
BM-derived cells 12.   
These stem cell therapies should be relevant for Wilson’s disease (WD). Due to 
ATP7B mutations, hepatobiliary copper (Cu) excretion is deficient in WD. This causes 
serious liver and/or brain damage 13.  In animal models, biliary Cu excretion in WD may be 
restored by gene therapy or by transplanting healthy hepatocytes 14-16. For instance, in LEC 
rats modeling hepatic WD, transplanted healthy hepatocytes repopulated liver with disease 
correction: Atp7b mRNA deficiency resolved; hepatic injury and fibrosis regressed14; 15. For 
transplanted hepatocytes to excrete Cu, reconstitution was necessary of bile canaliculi, This 
will be critical for treating WD with stem cells17.   
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To  determine the therapeutic potential of BM-derived hepatocytes, we used hepatic 
Cu toxicosis model of WD in Atp7b-/- mice 18. As after intrahepatic transplantation, BM-
derived nucleated cells were rapidly cleared from liver 19, we considered BM reconstitution 
will be better. After BMT, donor-derived stem cells should constantly appear in blood with 
recurrent opportunities for originating hepatocytes. In turn, these donor-derived hepatocytes 
should have proliferated as replacements for damaged and lost native hepatocytes.  
MATERIALS AND METHODS 
Animals: Animal Care and Use Committee of Albert Einstein College of Medicine 
approved protocols. Donor C57BL/6 mice were from National Cancer Institute (Bethesda, 
MD); transgenic C57BL/6-TgCAG-EGFP/1Osb/J mice expressing green fluorescent 
protein (GFP) were from Jackson Laboratories (Bar Harbor, ME). GFP+/- donors were 
used due to neurotoxicity in GFP+/+ mice. In GFP+/- mice 50% cells expressed GFP; 
correction factor of 2 was applied for donor-derived cells. Atp7b-/- mice were originally 
from S. Lutsenko. These were backcrossed 10 times into C57BL/6 background in Stem 
Cells, Animal Models and Cell Therapy Core. Animals received chow with 11.8 mg 
copper/kg (Ralston Purina, St. Louis, MO). 
BMT: Femur and tibia were flushed by Dulbecco’s Modified Eagle’s Medium 
containing 5% fetal bovine serum (DMEM; Life Technologies, Carlsbad, CA) with RBC 
lysis as described 20. Atp7b-/- mice of 6-7 weeks age, males and females in equal numbers, 
received total body irradiation (TBI) to 6 and 5 Gray in two sessions 3h apart. This was 
followed 8-10 x106 total BM cells in DMEM via tail vein. Death was not an end-point.  
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Hepatocyte transplantation: Donor GFP+ transgenic hepatocytes were isolated by 
collagenase perfusion 21. Freshly isolated 1x106 hepatocytes in 0.1 ml DMEM were 
transplanted into 6-7 week-old Atp7b-/- mice (n=6) via spleen. Animals were sacrificed for 
liver repopulation analysis after 1mo and 3 mo.  
GFP+ BM-derived cells and hepatocytes: Tissues were fixed in 4% 
paraformaldehyde in phosphate buffered saline, pH 7.4 (PAF) for 4h, immersed in 20% and 
30% sucrose for 2h and 36h, respectively, embedded in optimal cooling temperature (OCT) 
resin, and stored at −80°C. Cryosections of 5μm were post-fixed with PAF and stained with 
rabbit anti-GFP (1:300, Molecular Probes, Life Technologies) using for detection either 
Alexa Fluor®488-conjugated goat anti-rabbit IgG (1:500, Cat#A-11008, Molecular 
Probes), as described 20, or goat anti-rabbit IgG, horseradish peroxidase conjugate (1:500, 
AP187P, Sigma-Aldrich, St. Louis, MO) with DAB+ Substrate-Chromogen (Dako Inc., 
Carpinteria, CA). For donor-derived Kupffer cells (KC), monocytes or mesenchymal cells, 
GFP staining was followed by F4/80 staining with phycoerythrin-conjugated antibody 
(1:100, Cat#MF48004, Caltag Labs, U.K.), or vimentin staining with Alexa Fluor-647-
conjugated antibody (1:100, Cat#9856, Cell Signaling, MA). For donor-derived 
hepatocytes, GFP staining was followed by albumin staining with phycoerythrin-
conjugated anti-rabbit goat IgG (1:100, Cat#T6778, Sigma-Aldrich). Dipeptidylpeptidase-4 
(Dpp4) was stained with fluorescein isothiocynate-conjugated antibody (1:100, 
Cat#559652, BD Biosciences, San Diego, CA). Counterstaining used Fluorishield with 
DAPI (Cat#GTX30920 GeneTex, Irvine, CA). Morphometry used multiple tissue sections 
from several mice (n=3-4 each).  
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Liver histology and grading: Tissues were fixed in 10% buffered formalin for 
paraffin embedding and hematoxylin-eosin staining. Tissue grading included steatosis, 
polyploidy (megalocytes with enlarged nuclei containing >diploid DNA), apoptosis, and 
mitosis with maximal score of 13, as described 22.  
Hepatic fibrosis: Collagen was stained by Sirius Red (Picrosirius Red Stain Kit, 
Cat#24901, Polysciences Inc., PA), Stained areas were quantitated under x400 
magnification by ImageJ software (NCI, Bethesda, MD). Hydroxyproline was measured by 
a kit (MAK008, Sigma-Aldrich). 
Hepatic DNA damage. Tissue sections were fixed with ethanol and treated with 
250 ng/mL RNAse for 1h at 37oC. DNA was denatured by 4M HCl for 7 min followed by 
neutralization with 50 mM Tris base for 2 min. Sections were blocked with 10% goat serum 
in PBS for 1h and incubated with 8-oxo-dG antibody (1:1000, Cat-4354-MC-050, Clone 
2E2, Trevigen Inc, Gaithersburg, MD) overnight at room temperature. Detection used 
Alexa Fluor®647-conjugated goat anti-mouse IgG (1:100, Cat#4410, Cell Signaling, MA) 
for 1h with DAPI counterstaining.  
Hepatic Cu content: Tissue samples, 2-5 mg in weight, were desiccated and 
solubilized in 10 mM nitric acid, as described previously 23. Cu was measured by atomic 
absorption spectrometry with detection limit of 100 ng/g liver (Varian AA240, Varian 
Medical Systems, Palo Alto, CA).  
Reverse transcription (RT)-PCR: Total RNA was extracted by TRIzol Reagent 
(Invitrogen Corp, Carlsbad, CA), cleaned with RNeasy and treated with DNase (Qiagen 
Corp, Valencia, CA). cDNA was prepared from 1µg of RNA with Omniscript RT Kit 
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(Qiagen Corp, Valencia, CA). PCR cycles for Atp7b and Gapdh were: denaturation at 94oC 
x 3 min; 30 cycles at 94oC x 30s, 60oC x 45s, 72oC x 45s; and 72oC x 7 min. PCR products 
were resolved in 2% agarose. Quantitative RT-PCR for fibrosis and inflammation-related 
genes used QuantiTect® SYBR® Green PCR kit (CAT# 204143, Qiagen) with triplicate 
samples per condition. PCR cycles were: denaturation at 95°C x 10 min; 40 cycles at 95°C 
x 15s, 60°C x 60s; and 72oC x 10 min. Primers are listed (Table 1). Gene expression was 
normalized to Gapdh. Fold-differences used 2ΔΔCt method.  
Serological tests: Samples were stored at -20oC. A commercial kit was used for 
serum alanine aminotransferase activity (ALT) (Cat#700260, Cayman Chemical, Ann 
Arbor, MI). Serum ceruloplasmin was measured as described 14 
Statistical analysis: Data are shown as means ± SEM. Differences were analyzed 
by t-tests or analysis of variance (ANOVA) with Kruskall-Wallis test by GraphPad Prism7 
(Graph-Pad Software, La Jolla, CA). P<0.05 was considered significant. 
RESULTS 
With BMT, no fatality was observed over 2 weeks in Atp7b-/- mice. BM chimerism 
was >85%, as determined in randomly selected mice (n=5) by flow cytometry for GFP+ 
blood cells. This reproduced our experience with BMT protocol 20.   
We established groups of healthy C57BL/6 and Atp7b-/- mice (Fig. 1A). To reveal 
BM-derived cells, we analyzed mice 3 mo after BMT (n=3), and found GFP+ cells (Fig. 
1B).  These were mostly in hepatic sinusoids, i.e., KC or monocytes. GFP+ hepatocytes 
with large nuclei, abundant cytoplasm and albumin were infrequent (0-1 per section). 
Donor-derived hepatocytes displayed Dpp4+ bile canaliculi. When adult hepatocytes were 
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transplanted, cells engrafted next to portal areas. After 1mo, 2±3 transplanted hepatocytes 
were in each group. Transplanted hepatocytes after 3 mo constituted larger groups; 35±28 
cells each, p<0.001. Thus, in Atp7b-/- mice healthy hepatocytes proliferated. 
In untreated Atp7b-/- controls (n=40), 3 mice (7%) died spontaneously over 12 mo. 
In Atp7b-/- mice plus BMT (n=53), 27 mice (51%) died over 12 mo, p<0.001. No mortality 
was observed in healthy C57BL/6 mice.  
Serum ALT in healthy C57BL/6 mice (n=4) was 54±17 u/L (Fig. 1C). ALT levels 
in untreated Atp7b-/- mice (n=8) were higher, 172±36 u/L, p<0.001. After BMT, ALT 
levels were higher still, after 6 mo (n=8) and 12 mo (n=4), 447±127 u/L and 214±110 u/L, 
respectively. Ceruloplasmin levels were lower in Atp7b-/- mice with or without BMT 
versus C57BL/6 controls (Fig. 1D). 
Liver fibrosis accelerated in Atp7b-/- mice after BMT  
Untreated Atp7b-/- mice showed multiple WD-associated changes. In Atp7b-/- mice 
with BMT, liver histology worsened (Fig. 2A). Megalocytosis marking advanced 
polyploidy was prominent after BMT. Sirius Red showed more fibrosis after BMT (Fig. 
2B). Histological grading after 12 mo, was: 2±0, 6.3±0.3 and 7.9±0.3 in healthy C57BL/6 
(n=9), untreated Atp7b-/- controls (n=8) and Atp7b-/- mice with BMT (n=7), respectively, 
p<0.001, ANOVA (Fig. 2C). Sirius Red area in healthy controls (n=9) was 8.7±0.9%, rising 
in Atp7b-/- mice (n=8) and Atp7b-/- mice with BMT (n=7) to 31.7±2.2% and 38.3±0.9%, 
respectively, p<0.001, ANOVA. Hepatic hydroxyproline increased from 0.2±0.1 mg/g in 
C57BL/6 mice (n=4) by 2.5-, 4.5- and 3.5-fold in Atp7b-/- controls or mice 6 mo and 12 mo 
after BMT (n=4 ea), respectively, p<0.001, ANOVA (Fig. 2D). 
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Hepatic Cu content, Atp7b mRNA expression and cell damage 
Healthy C57BL/6 mice (n=9) had 0.016±0.00 mg Cu/g liver after 12 mo. In 
untreated Atp7b-/- controls (n=8), significantly more Cu was found, 0.18±0.01 mg/g, 
p<0.001. In Atp7b-/- mice with BMT, liver Cu was even higher, both after 6 mo (n=9) and 
12mo (n=7), 0.26±0.05 mg/g and 0.38±0.05 mg/g, respectively, p<0.05 (Fig. 3A). Atp7b 
mRNA was present in only healthy C57BL/6 mice and not untreated Atp7b-/- or Atp7b-/- 
mice with BMT (n=3 ea) (Fig. 3B). This suggested donor-derived hepatocytes did not 
repopulate liver after BMT. To determine the basis for lack of proliferation in native 
hepatocytes, we examined oxidative DNA damage, which results from Cu toxicosis, and 
impairs liver regeneration 24 (Fig. 3C). In healthy C57BL/6 mice, hepatic 8-oxo-dG adducts 
were not prominent. Atp7b-/- mice showed considerable 8-oxo-dG adducts, particularly in 
megalocytes or polyploid cells and also in inflammatory and stromal cells. This damage in 
native hepatocytes was more pronounced in Atp7b-/- mice with BMT. Losses of these cells 
should have led to greater compensatory proliferation in healthy donor-derived hepatocytes.  
Inflammation and fibrosis-related genes were expressed more after BMT 
Genes contributing to inflammation (IL6, TNF-α) and fibrogenesis (TGF-β, MMP2, 
TIMP1 and COL1) were expressed more in Atp7b-/- mice versus healthy controls (n=3 ea) 
(Fig. 4). IL6, TNF-α, and TGF-β were expressed even more in Atp7b-/- mice after BMT 
(n=3) – more after 6 mo versus 12 mo - fibrotic tissue in latter samples could have affected 
gene expression. As inflammation likely recruited cell types aggravating fibrosis, MMP2, 
TIMP1 and COL1 expression profiles were in agreement with this possibility.  
Replacement of liver cell types by donor BM-derived cells  
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Donor-derived GFP+/Dpp4+ hepatocytes were still surprisingly rare after 12 mo. In 
Atp7b-/- mice with BMT we observed neither proliferating donor-derived cells nor liver 
repopulation (Fig. 5A). GFP+ donor cells were mostly in hepatic sinusoids with F4/80+ 
monocytes or macrophages (Fig. 5B). GFP+/vimentin+ mesenchymal cells, including 
myofibroblasts, were also abundant (Fig. 5C).  
Morphometry indicated donor-derived cell types 12 mo after BMT constituted 
Dpp4+ hepatocytes in <0.05%, F4/80+ monocytes/macrophages in 14%, and vimentin+ 
mesenchymal cells in 84% of the cases (Table 2). 
DISCUSSION 
Donor BM generated multiple cell types in Atp7b-/- mice, although hepatocytes 
were infrequent, which was similar to previous reports 3; 20. Extensive BM chimerism along 
with numerous monocytes/macrophages indicated BMT was successful. The contribution 
of TBI for replacing native BM is critical. Although TBI may cause early inflammation and 
endothelial injury (later, veno-occlusive disease, VOD); after successful BMT, these 
complications abate or resolve. Long-term hepatic damage after TBI is limited - after one 
year mice exhibit only mitosis 25. Alternatively, BMT may use drug myeloablation, e.g., 
busulfan and cyclophosphamide 26. However, VOD may actually be more severe with these 
drugs, as opposed to TBI. That was not the case in our study.  
In pluripotent stem cells, hepatic differentiation is restricted, at best, to early-stage 
fetal hepatocytes in vitro 9; 27. Stem cell differentiation is aided by additional signals and 
cues in vivo. This differentiation is achieved by incompletely understood and complex 
mechanisms, including transcription factor regulation, protein-protein interactions, RNA-
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protein changes, DNA methylation, epigenetic reprogramming, etc 27. These mechanisms 
are difficult, if not impossible, to decipher in rare donor-derived cells in vivo.  
Presence of Dpp4+ bile canaliculi in BM-derived hepatocytes indicated maturity 10; 
11. To date, no study has utilized this stringent marker in WD of Dpp4+ bile canaliculi for 
stem cell-derived hepatocytes. This structure-based analysis should be significant as gene 
expression alone to characterize cell maturity has often been inadequate 6; 8; 9. Lack of 
hepatic Atp7b mRNA and continued Cu accumulation after BMT were prominent in our 
study. Histological abnormalities also worsened after BMT. This differed from toxic milk 
mouse model of Cu toxicosis, where transplantation of healthy BM in sublethally irradiated 
recipients decreased hepatic Cu 28. The fate of transplanted BM-derived cells in that study 
was not evaluated. Also, it was unknown whether Cu was excreted in bile.   
Proliferation restriction in BM-derived hepatocytes was another issue for 
therapeutic benefits. Inability of BM-derived hepatocytes to correct disease in Atp7b-/- 
mice concerned two major processes: 1) donor BM-derived hepatocytes with bile canaliculi 
were uncommon, and 2) proliferation in BM-derived hepatocytes was restricted. Anti-
proliferative effects of Cu, potential growth factor deficiencies, ECM alterations, 
inflammation, or other changes were likely contributors.  
A major difference in animal models of WD (Atp7b-/- mice) versus tyrosinemia 
(Fah-/- mice) is that Cu toxicosis causes intracellular injury plus extracellular perturbations 
due to tissue inflammation, fibrosis and ECM changes 14; 15. In the Fah-/- state, toxic 
tyrosine metabolites are restricted to hepatocytes without such inflammation or fibrosis 29. 
Similar considerations apply to mice with mutant alpha-1 antitrypsin and intracellular 
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injury 12. We did not focus on whether BM-derived cells fused with native hepatocytes, as 
in Fah-/- mice 30. This cell fusion had not interfered with disease correction 3.  
In LEC rat model of WD, transplanted hepatocytes repopulate liver, and hepatic 
radiation or other pro-oxidant treatments, in fact, accelerates proliferation in transplanted 
hepatocytes 14; 15.  Similarly, healthy hepatocytes proliferated in Atp7b-/- mice. As Cu alters 
ECM to impair cell survival and/or proliferation 31, this might have affected donor-derived 
hepatocytes.  Remote TBI should not have directly injured donor-derived hepatocytes. 
Hepatic radiation in excess of that after TBI did not exacerbate fibrosis in LEC rats 14; 15.   
Tissue inflammation triggers multiple cytokine, chemokine and receptor-mediated 
events driving fibrogenesis. The GFP+/F4/80+ macrophages/monocytes and 
GFP+/vimentin+ mesenchymal cells in Atp7b-/- mice after BMT should have contributed to 
inflammatory cytokines and fibrogenesis. Inflammatory cytokines and chemokines, 
including TNFα and IL6, from activated neutrophils and KC impair hepatocyte survival and 
liver repopulation 32; 33. Previous studies of hepatic stellate cells (HSC) indicated these play 
important roles in ECM remodeling during cell engraftment in liver 34. HSC release 
deleterious cytokines during fibrogenesis, e.g., TGFβ, to suppress hepatocyte proliferation 
35. This might have affected proliferation in donor-derived cells in WD. Activation of HSC 
promotes expansion of myofibroblasts, which was reproduced by donor BM-derived cells 
in hepatic fibrosis 36. Similarly, exposure of transplanted HSC to fibrogenic injuries in the 
liver led to their conversion into myofibroblasts, along with recruitment of monocytes and 
KC to further exacerbate hepatic fibrosis 37. Targeting of donor-derived myofibroblasts 
involves ligand-receptor interactions, e.g., cannabinoid receptors 38.  Altered expression of 
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matrix degrading enzymes (MMP, TIMP) and of collagen in Atp7b-/- mice after BMT was 
in agreement with contribution of inflammatory cell types in hepatic fibrosis.  
Stem cell transplantation is of interest for chronic liver disease 7, although trials of 
hematopoietic or mesenchymal stem cells (MSC) have not shown clear benefits 39. In one 
animal study, BM-derived healthy MSC expressing Atp7b 40, improved their survival and 
proliferation. In another study, transplantation of Atp7b-transduced MSC in LEC rats 41, 
decreased liver Cu over the short-term. Our work in Atp7b-/- mice indicates analysis of 
candidate stem cells in representative settings will be helpful for clinical trials. 
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 Table 1 
  
RT-PCR primers 
 
Gene 
(NCBI ID) 
Primers 
Amplicon 
Size 
Tm 
(ºC) 
Tgfβ1 
(21803) 
Forward: 5’-CTCCCGTGGCTTCTAGTGC-3’ 
Reverse: 5’-GCCTTAGTTTGGACAGGATCTG-3’ 
133 60 
Collagen type 1 
(12842) 
Forward: 5’-GCTCCTCTTAGGGGCCACT-3’ 
Reverse: 5’-CCACGTCTCACCATTGGGG-3’ 
103 60 
Timp1 
(21857) 
Forward: 5’-CGAGACCACCTTATACCAGCG-3’ 
Reverse: 5’-ATGACTGGGGTGTAGGCGTA-3’ 
108 60 
Mmp2 
(17390) 
Forward: 5’-ACCTGAACACTTTCTATGGCTG-3’ 
Reverse: 5’-CTTCCGCATGGTCTCGATG-3’ 
140 60 
Tnf 
(21926) 
Forward: 5’-CAGGCGGTGCCTATGTCTC-3’ 
Reverse: 5’-CGATCACCCCGAAGTTCAGTAG-3’ 
89 60 
Il6 
(16193) 
Forward: 5’-TCTATACCACTTCACAAGTCGGA-3’ 
Reverse: 5’-GAATTGCCATTGCACAACTCTTT-3’ 
88 60 
Atp7b 
(11979) 
Forward: 5’-GGGGACGATGCCTGAACAG-3’  
Reverse, 5’-TAGCCAACATTGTCGAAGGCG-3’ 
135 60 
Gapdh 
(2597) 
Forward: 5’-GGCCTCCAAGGAGTAAGACC-3’ 
Reverse: 5’-AGGGGTCTACATGGCAACTG-3’ 
127 60 
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Table 2 
Morphometry for donor-derived cells in liver of Atp7b-/- mice 1 year after BMT* 
Donor-derived 
cell type 
Number GFP+ 
donor BM cells 
per high power 
field, means ± 
SEM (n)*  
Number GFP+ / 
hepatic marker+ 
donor BM-
derived cells per 
high power field* 
Percent of 
GFP+ cells 
(mean)  
 
P values 
(ANOVA)** 
Hepatocytes 
with DPPIV+ 
bile canaliculi  
136 ± 2 
(n=61) 
0.05 ± 0.0 0.04 
 
- 
F4/80+ Kupffer 
cells and 
monocytes  
142 ± 2 
(n=40) 
20 ± 1 14 <0.001 
Vimentin+ 
mesenchymal 
cells  
154 ± 2 
(n=47) 
129 ± 2 84 <0.001 
*Cell numbers were multiplied by factor of 2 because 50% of GFP+/- transgenic 
donor cells expressed GFP 
**p values versus percent of GFP+ hepatocytes 
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FIGURE LEGENDS 
 
Fig. 1. Animal outcomes after BMT. (A) Experimental plan and timeline, 
including animal groups, and end-points over 12 mo study period. (B) GFP expression in 
hepatocytes and other cell types in donor liver (top left panel; inset, GFP+ cell in hepatic 
sinusoid, arrow). GFP was absent in C57BL/6 or Atp7b-/- controls (top middle panel). 
Transplanted GFP+ hepatocytes after 3 mo in Atp7b-/- mice forming expanding cluster 
(arrow, top right panel, DAB color development). GFP+ donor-derived cells in Atp7b-/- 
mice 3 mo after BMT (inset in panel at bottom left: arrow, GFP+ hepatocyte). GFP and bile 
canalicular Dpp4 (red) in Atp7b-/- mouse 3 mo after BMT (magnified view of boxed area: 
arrow, GFP+/Dpp4+ hepatocyte; arrowhead, Dpp4+ sinusoidal cell). Original 
magnification: top panels x600; bottom panels, x400. DAPI counterstain.  (C) Serum ALT 
levels were elevated in Atp7b-/- mice and increased after BMT. (D) Serum ceruloplasmin 
was lower in Atp7b-/- mice with or without BMT than healthy controls.  P values, ANOVA, 
Kruskall-Wallis test. 
Fig. 2. Liver histology after 12 mo. (A) Healthy C57/BL6 mice showed normal 
morphology (left, inset, arrow, size of normal nuclei). Liver injury was evident in Atp7b-/- 
mice, including after BMT (insets, megalocytes with enlarged nuclei). (B) Sirius Red 
staining showed more collagen in untreated Atp7b-/- controls and Atp7b-/- mice after BMT. 
Original magnification, x400. (C) Grading for tissue histology indicated worsening in 
Atp7b-/- mice after BMT. (D) Tissue hydroxyproline levels were higher in Atp7b-/- mice 
than healthy controls. These increased in mice after BMT.  P values, ANOVA with 
Kruskall-Wallis test. 
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Fig. 3. Hepatic Cu and Atp7b mRNA with changes in liver cells. (A) Compared 
with healthy C57BL/6 mice liver Cu content increased in Atp7b-/- controls and Atp7b-/- 
mice after BMT. (B) RT-PCR revealed Atp7b mRNA in healthy C57BL/6 mice but in 
neither untreated Atp7b-/- mice nor Atp7b-/- mice after BMT. (C) Oxidative DNA damage 
with 8-oxo-dG adducts in liver (red color) in Atp7b-/- mice after 12 mo, including in 
hepatocytes and inflammatory or stromal cells. These adducts were abundant in Atp7b-/- 
mice after BMT. Chart provides cumulative analysis for adducts. Original magnification, 
x400. DAPI counterstain. 
Fig. 4. Quantitative RT-PCR for inflammatory and fibrogenic genes. Gene 
expression normalized to Gapdh in C57BL/6 and Atp7b-/- control mice and Atp7b-/- mice 6 
mo or 12 mo after BMT. IL6 and TNF-α were expressed more after BMT. Similarly, TGF-
β, TIMP1 and collagen1 were expressed more, but MMP2 was expressed less after BMT, 
indicating fibrogenesis-associated processes. These changes were more pronounced at 6 mo 
after BMT. Whether more fibrosis at later times introduced sampling issues was not 
excluded. P values, ANOVA with Kruskall-Wallis test. 
Fig. 5. Donor BM-derived cell types in liver after 12 mo. (A) GFP and Dpp4 
staining for bile canaliculi (red color) in hepatocytes. GFP+/Dpp4+ cells did not expand or 
form clusters after BMT. (B) F4/80 (red) in donor-derived monocytes/macrophages (inset, 
arrow, GFP+/F4/80+ cell in sinusoid). (C) Costaining for vimentin (red) with green/yellow 
donor-derived myofibroblasts throughout liver (inset, arrow, donor-derived myofibroblast). 
Original magnification, x400. DAPI counterstain. 
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